1. Home
  2. VOD vs NTRA Comparison

VOD vs NTRA Comparison

Compare VOD & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vodafone Group Plc

VOD

Vodafone Group Plc

HOLD

Current Price

$15.68

Market Cap

36.3B

ML Signal

HOLD

Logo Natera Inc.

NTRA

Natera Inc.

HOLD

Current Price

$274.48

Market Cap

39.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VOD
NTRA
Founded
1984
2003
Country
United Kingdom
United States
Employees
91128
N/A
Industry
Telecommunications Equipment
Medical Specialities
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
36.3B
39.1B
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
VOD
NTRA
Price
$15.68
$274.48
Analyst Decision
Sell
Strong Buy
Analyst Count
3
15
Target Price
N/A
$259.07
AVG Volume (30 Days)
5.1M
1.1M
Earning Date
06-05-2026
05-07-2026
Dividend Yield
3.24%
N/A
EPS Growth
N/A
0.65
EPS
N/A
N/A
Revenue
N/A
$210,939,000.00
Revenue This Year
$11.47
$18.08
Revenue Next Year
$5.90
$19.65
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.00
$136.21
52 Week High
$16.61
$288.04

Technical Indicators

Market Signals
Indicator
VOD
NTRA
Relative Strength Index (RSI) 56.55 60.57
Support Level $14.49 $186.96
Resistance Level $15.85 $288.04
Average True Range (ATR) 0.28 11.31
MACD 0.03 -0.95
Stochastic Oscillator 45.98 79.95

Price Performance

Historical Comparison
VOD
NTRA

About VOD Vodafone Group Plc

Vodafone operates mobile and fixed-line networks and businesses across Europe, Africa, and the Middle East. Its largest market is Germany, where it is the second mobile operator after Deutsche Telekom and owns two cable networks after acquiring Kabel Deutschland in 2013 and Liberty Global Germany in 2019. In the UK, Vodafone merged with CK Hutchison in 2024, consolidating the mobile market. It also divested its Spanish and Italian divisions in that same year, given their low returns on invested capital.

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Share on Social Networks: